ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
In what is becoming a crowded market, Moderna announced positive top-line Phase 3 data for its messenger RNA (mRNA) respiratory syncytial virus (RSV) vaccine, which was tested in people aged 60 and over. The announcement comes amid efforts by other companies to develop their own vaccine candidates. Last year, Pfizer and GSK separately reported positive trial outcomes for their RSV products that are intended for older adults. Moderna plans to apply for regulatory approval for its vaccine candidate in the first half of 2023.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X